Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.
作者信息
Cheng Pin-Nan, Yu Ming-Lung
机构信息
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2024 Apr;30(2):144-146. doi: 10.3350/cmh.2024.0115. Epub 2024 Feb 19.
Abstract
摘要
相似文献
1
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer.替诺福韦酯或替诺福韦艾拉酚胺在慢性乙型肝炎患者中的心血管风险：问题多于答案。
Clin Mol Hepatol. 2024 Apr;30(2):144-146. doi: 10.3350/cmh.2024.0115. Epub 2024 Feb 19.
2
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply.信函：富马酸替诺福韦二吡呋酯或富马酸替诺福韦艾拉酚胺在慢性乙型肝炎患者中的心血管风险：问题多于答案——作者回复
Clin Mol Hepatol. 2024 Apr;30(2):272-273. doi: 10.3350/cmh.2024.0123. Epub 2024 Feb 21.
3
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯治疗 HBeAg 阳性慢性乙型肝炎病毒感染：一项随机、双盲、III 期、非劣效性试验。
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22.
4
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯治疗 HBeAg 阴性慢性乙型肝炎病毒感染患者的随机、双盲、III 期非劣效性试验。
Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22.
5
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.在病毒学抑制的慢性乙型肝炎患者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺：一项随机、双盲、III 期、多中心非劣效性研究。
Lancet Gastroenterol Hepatol. 2020 May;5(5):441-453. doi: 10.1016/S2468-1253(19)30421-2. Epub 2020 Feb 20.
6
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯在管理慢性乙型肝炎方面的比较，以及患者人口统计学的最新趋势。
Expert Rev Gastroenterol Hepatol. 2017 Nov;11(11):999-1008. doi: 10.1080/17474124.2017.1386554. Epub 2017 Oct 8.
7
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.在慢性乙型肝炎感染患者中，经过 96 周的治疗，未检测到对替诺福韦艾拉酚胺的耐药性。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01064-18. Print 2018 Oct.
8
Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.恩替卡韦或替诺福韦停药后丙酚替诺福韦、恩替卡韦和富马酸替诺福韦二吡呋酯的再治疗疗效及肾脏安全性
Dig Dis Sci. 2023 Feb;68(2):665-675. doi: 10.1007/s10620-022-07657-8. Epub 2022 Aug 17.
9
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺治疗的慢性乙型肝炎患者的心血管风险。
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
10
Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.替诺福韦艾拉酚胺、替诺福韦二吡呋酯和恩替卡韦治疗乙型肝炎相关慢加急性肝衰竭的短期和长期安全性和疗效。
BMC Infect Dis. 2021 Jun 14;21(1):567. doi: 10.1186/s12879-021-06237-x.
引用本文的文献
1
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B.从先前的核苷（酸）类似物转换为替诺福韦艾拉酚胺对慢性乙型肝炎患者血脂水平和心血管风险的影响。
PLoS One. 2025 May 27;20(5):e0324897. doi: 10.1371/journal.pone.0324897. eCollection 2025.
2
Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide".对关于“富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺治疗慢性乙型肝炎患者的心血管风险”的信件的回复
Clin Mol Hepatol. 2024 Oct;30(4):1031-1032. doi: 10.3350/cmh.2024.0228. Epub 2024 Apr 11.
3
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply.信函：富马酸替诺福韦二吡呋酯或富马酸替诺福韦艾拉酚胺在慢性乙型肝炎患者中的心血管风险：问题多于答案——作者回复
Clin Mol Hepatol. 2024 Apr;30(2):272-273. doi: 10.3350/cmh.2024.0123. Epub 2024 Feb 21.
本文引用的文献
1
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide.富马酸替诺福韦二吡呋酯或替诺福韦艾拉酚胺治疗的慢性乙型肝炎患者的心血管风险。
Clin Mol Hepatol. 2024 Jan;30(1):49-63. doi: 10.3350/cmh.2023.0328. Epub 2023 Nov 20.
2
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.富马酸替诺福韦二吡呋酯换用替诺福韦艾拉酚胺后慢性乙型肝炎患者的体重增加和代谢紊乱。
Aliment Pharmacol Ther. 2024 Jan;59(2):230-238. doi: 10.1111/apt.17765. Epub 2023 Oct 16.
3
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.台湾肝病研究学会-台湾心脏学会代谢相关脂肪性肝病与心血管疾病管理之立场声明。
Clin Mol Hepatol. 2024 Jan;30(1):16-36. doi: 10.3350/cmh.2023.0315. Epub 2023 Oct 4.
4
Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study.脂肪肝的严重程度与高血压和糖尿病风险高度相关：一项横断面和纵向队列研究。
Hepatol Int. 2024 Feb;18(1):138-154. doi: 10.1007/s12072-023-10576-z. Epub 2023 Sep 25.
5
Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients.在慢性乙型肝炎病毒患者中，与恩替卡韦治疗相比，替诺福韦艾拉酚胺显著提高了血脂水平。
World J Hepatol. 2023 Aug 27;15(8):964-972. doi: 10.4254/wjh.v15.i8.964.
6
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.长期替诺福韦艾拉酚胺治疗慢性乙型肝炎可实现高病毒抑制率，并具有良好的肾脏和骨骼安全性。
Am J Gastroenterol. 2024 Mar 1;119(3):486-496. doi: 10.14309/ajg.0000000000002468. Epub 2023 Aug 9.
7
Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study.亚洲慢性乙型肝炎患者长期抗病毒治疗与匹配对照患者的可比死亡率：一项基于人群的研究。
Am J Gastroenterol. 2023 Jun 1;118(6):1001-1009. doi: 10.14309/ajg.0000000000002074. Epub 2022 Oct 25.
8
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis.替诺福韦艾拉酚胺治疗可能不会恶化慢性乙型肝炎患者的血脂情况：一项倾向评分匹配分析。
Clin Mol Hepatol. 2022 Apr;28(2):254-264. doi: 10.3350/cmh.2021.0314. Epub 2021 Dec 28.
9
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.转换为替诺福韦艾拉酚胺/恩曲他滨/利匹韦林、替诺福韦艾拉酚胺/恩曲他滨/埃替拉韦/考比司他以及阿巴卡韦/拉米夫定/多替拉韦对HIV感染者心血管风险和血脂谱的影响：一项回顾性队列研究
BMC Infect Dis. 2021 Jun 22;21(1):595. doi: 10.1186/s12879-021-06304-3.
10
Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load.无论病毒载量如何，肝脂肪变性都是慢性乙型肝炎患者死亡率和癌症的有力预测指标。
JHEP Rep. 2019 Mar 19;1(1):9-16. doi: 10.1016/j.jhepr.2019.02.002. eCollection 2019 May.
Zotero 插件